Min Zhang

This paper identifies a novel non-canonical RT-loop degron in VAV1 and demonstrates how conformational restriction and computational modeling enhance molecular glue potency for proteasomal degradation.

This study develops LD5095, a novel cereblon-recruiting RIPK1 degrader, showing potent RIPK1 degradation and tumor sensitization to immune checkpoint inhibitors.

This study designs and evaluates a novel RIPK1 degrader, LD5097, showing potent degradation activity, favorable pharmacokinetics, and enhanced antitumor effects in cancer models.

This study evaluates AlphaFold3's performance in drug discovery tasks, finding it excels at static protein-ligand interactions but struggles with conformational changes, GPCR bias, and affinity ranking.

The paper challenges the validation of ZYS-1 as an ADAR1 inhibitor, showing it lacks inhibitory activity in validated assays.